Olvi-Vec Induces Promising Response in Advanced Ovarian Cancer
Olvimulogene nanivacirepvec virotherapy plus chemotherapy with or without bevacizumab produces a manageable safety profile in platinum-resistant or platinum-refractory ovarian cancer in the phase 2 VIRO-15 trial.
Oncology On-The-Go Podcast: Nursing-Led Palliative Care in Advanced Cancer
Margaret Rosenzweig, PhD, CRNP-C, AOCNP, FAAN, discusses how nursling-led palliative care may improve advanced cancer care planning uptake based on a secondary analysis of the CONNECT study.
The ‘Golden Age’ of Daratumumab: Highlights From an Expert Panel on Multiple Myeloma
A Satellite Sessions program at the Yale Cancer Center discusses treatment paradigms and unmet needs in multiple myeloma as well as transplantation, bispecific T-cell engaging therapies, and the importance of collaborative decision-making in clinical practice.
Oncology On-The-Go Podcast: De-escalating Breast Cancer Treatment
Rakhshanda Rahman, MD, FRCS, FACS, emphasizes the importance of educating patients and physicians on the potential risks and benefits of new approaches and technologies involved in the de-escalation of breast cancer treatment.
Data Support ctDNA-Based Adaptive Strategies for EGFR+ Advanced NSCLC
Longitudinal ctDNA assessments may be a relevant tool for making treatment decisions for patients with EGFR-mutated non–small cell lung cancer based on findings from the phase 2 APPLE trial.
FDA Accepts sBLA for Pembrolizumab/Chemo in Advanced Biliary Tract Cancer
The regulatory agency has set a Prescription Drug User Fee Act date of February 7, 2024 for pembrolizumab plus chemotherapy as a treatment for patients with advanced or metastatic biliary tract cancer.
2 Clarke Drive Cranbury, NJ 08512